Review tracks diversification of kratom products and associated health concerns

Why it matters

The review distinguishes native leaf, extracts, and isolates, a practical distinction for clinicians and policymakers assessing products sold under the same “kratom” label. It is a review, not a direct comparative clinical trial.

The big picture

The commercial kratom market has expanded beyond traditional leaf preparations to extracts, edibles, resins, and isolated alkaloids. Product concentration and formulation can affect exposure, yet real-world labeling and product standardization remain variable.

Key findings

• The review reports increased diversification of kratom products since 2021.
• Native leaf powder and extract derivatives remain the primary kratom product types in the US and Europe.
• The authors describe growth in chemically altered products, including enriched extracts, edibles, resins, and isolates.
• They report total alkaloid content of 2% to 5% by weight for native leaf, versus extracts containing five to 50 times as much alkaloid content.
• The review identifies purified mitragynine and semi-synthetic 7-hydroxymitragynine as products likely associated with greater dependence and overdose potential.

What they say

The authors summarize that extracts can contain “five to 50 times the alkaloid content of the native leaf.”

Bottom line

Evidence and risks cannot be assumed to transfer across leaf, extract, and isolate products simply because all are marketed as kratom.